(NASDAQ: BVS) Bioventus's forecast annual revenue growth rate of 6.95% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.76%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Bioventus's revenue in 2026 is $568,087,000.On average, 6 Wall Street analysts forecast BVS's revenue for 2026 to be $50,790,113,573, with the lowest BVS revenue forecast at $49,082,945,755, and the highest BVS revenue forecast at $52,928,854,746. On average, 6 Wall Street analysts forecast BVS's revenue for 2027 to be $54,375,748,075, with the lowest BVS revenue forecast at $52,264,447,982, and the highest BVS revenue forecast at $57,373,478,218.
In 2028, BVS is forecast to generate $57,717,739,045 in revenue, with the lowest revenue forecast at $55,952,362,874 and the highest revenue forecast at $60,057,714,807.